Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
Go back to Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 41.23 -1.56 (3.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.79 | 52 Week High | $71.49 | |||
| Open | $42.93 | 52 Week Low | $33.50 | |||
| Day High | $42.93 | P/E | N/A | |||
| Day Low | $40.26 | EPS | $-1.18 | |||
| Volume | 1,133,852 | |||||
